GWPH News and Press, GW Pharmaceuticals Plc From 08/06/20

- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month - - Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceutic...

Despite everything that has happened so far this year, major indexes are trading near record highs once more. While a rising tide lifts all ships, it can be a bit trickier for investors to single out the most promising companies from the rest of the businesses out there on the market. One indus...

GW Pharmaceuticals (NASDAQ: GWPH ) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is -$0.04  vs. $0.21 and the consensus Revenue Estimate is $124.26M (+72.5% Y/Y). Analyst expects R&D expense of $47.1M. ...

Listen on the go! Subscribe to The Cannabis Investing Podcast on Apple Podcasts , Google Podcasts , Spotify , and Stitcher . By Rena Sherbill Rahul Bhushan co-founded Rize ETF and has a wealth of experience in systematic strategies, indexing and E...

The FDA just approved GW Pharmaceuticals (GWPH) Epidiolex Oral Solution to treat seizures associated with Tuberous Sclerosis Complex. This is the third approval for the drug. On Monday, GW Pharmaceuticals ( GWPH ) announced that the FDA had approved Epidiolex Oral Solution to treat sei...

August 4, 2020 Palm Beach, FL – August 4, 2020 – The cannabis infused products market is expected to gain market growth in the forecast period of 2020 to 2027. A recent report from industry insider Date Bridge market Research also says that the CBD Oil Extract Market...

Shares of GW Pharmaceuticals (NASDAQ: GWPH) are up by 4.8% as of 3:18 p.m. EDT on Monday, after rising by as much as 5.5% earlier in the day. The catalyst for these nice gains is the fact that the U.S. Food and Drug Administration (FDA) approved GW Pharma's Epidiolex for the treatment of sei...

GW Pharmaceuticals ' (NASDAQ: GWPH) cannabidiol (CBD) drug Epidiolex has been granted Food and Drug Administration approval for a new indication. Additionally, its previous approval has been expanded to cover a wider age range of patients. The company announced Monday morning that the FDA ha...

Fluidigm receives NIH funding for COVID-19 testing technology Fluidigm Corporation ( FLDM ) announced that it has inked a letter contract with the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering. The contract pertains to a probable project under...

– Age-range for all EPIDIOLEX indications expanded to include patients  one year of age and older – – Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine –                 ...